Chemistry:Orelabrutinib
From HandWiki
Orelabrutinib is a drug for the treatment of cancer.
In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]
Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.[2]
References
- ↑ "Orelabrutinib: First Approval". Drugs 81 (4): 503–507. March 2021. doi:10.1007/s40265-021-01482-5. PMID 33704654.
- ↑ "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances 7 (16): 4349–4357. August 2023. doi:10.1182/bloodadvances.2022009168. PMID 37078706.
 |  |
